Explore 6 key points about Austedo (deutetrabenazine) for Tardive Dyskinesia. Understand how it works, its use, and important considerations. Consult a healthcare professional.
Austedo and Tardive Dyskinesia: 6 Key Points for Understanding Treatment
Tardive Dyskinesia (TD) is a neurological disorder characterized by involuntary, repetitive body movements. It often develops as a side effect of long-term use of certain medications, particularly older antipsychotics and some anti-nausea drugs. The condition can significantly impact a person's quality of life. Austedo (deutetrabenazine) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Tardive Dyskinesia in adults. Understanding how Austedo works and its role in managing TD is crucial for both patients and caregivers. This article outlines six key points regarding Austedo and its application in treating Tardive Dyskinesia.
1. Understanding Tardive Dyskinesia (TD)
Tardive Dyskinesia manifests as involuntary and often repetitive movements of the face, trunk, and limbs. These movements can include grimacing, blinking, tongue protrusion, lip smacking, rapid arm and leg movements, and twisting motions of the torso. TD is considered a chronic condition, and its symptoms can range from mild to severe. It typically develops after months or years of taking certain medications that block dopamine receptors in the brain, although it can sometimes emerge after shorter exposure or even after discontinuing the medication.
2. What is Austedo (Deutetrabenazine)?
Austedo is the brand name for the generic drug deutetrabenazine. It belongs to a class of medications known as vesicular monoamine transporter 2 (VMAT2) inhibitors. Approved in 2017 for the treatment of Tardive Dyskinesia, Austedo is an oral medication that helps to reduce the involuntary movements associated with the condition. It is not a cure for TD, but rather a treatment designed to manage and reduce the severity of symptoms.
3. How Austedo Works in TD Management
Austedo works by selectively inhibiting VMAT2, a protein responsible for packaging neurotransmitters like dopamine into vesicles for release in the brain. By reducing the amount of dopamine available to overactive dopamine receptors, Austedo helps to regulate nerve signals that contribute to the uncontrolled movements seen in Tardive Dyskinesia. This mechanism aims to restore a more balanced neurotransmitter activity, thereby reducing the frequency and severity of dyskinetic movements.
4. Key Considerations for Austedo Treatment
Treatment with Austedo typically begins with a low dose, which is then gradually increased by a healthcare professional until an effective dose is reached or side effects become unmanageable. This process, known as titration, allows the body to adjust to the medication. Individual responses to Austedo can vary, and it is important for patients to adhere to their prescribed dosage schedule and report any changes in symptoms or side effects to their doctor. Austedo is often part of a broader management plan for TD, which may also involve reviewing and adjusting other medications that might be contributing to the condition.
5. Important Safety Information and Monitoring
As with any prescription medication, Austedo has potential side effects and contraindications. Common side effects may include somnolence (sleepiness), diarrhea, dry mouth, and fatigue. More serious potential side effects can include depression, suicidal thoughts, worsening of Parkinsonism, and QT prolongation (an electrical problem in the heart). Austedo is not recommended for individuals with certain conditions, such as severe liver impairment or those taking specific interacting medications. Regular monitoring by a healthcare professional is essential to assess the medication's effectiveness, manage side effects, and ensure patient safety throughout the course of treatment.
6. The Role of a Healthcare Professional
The diagnosis and management of Tardive Dyskinesia, including the decision to prescribe Austedo, must always be made by a qualified healthcare professional. A doctor will evaluate a patient's medical history, current medications, and the nature of their involuntary movements to determine if Austedo is an appropriate treatment option. They will also provide guidance on proper dosing, potential interactions with other medications, and what to expect during treatment. Open communication between the patient and their doctor is vital for effective and safe management of TD with Austedo.
Summary
Austedo (deutetrabenazine) represents a significant advancement in the management of Tardive Dyskinesia, a challenging movement disorder. By selectively inhibiting VMAT2, it helps to reduce the involuntary movements that characterize TD. Key aspects of its use include a careful titration process, awareness of potential side effects, and the necessity of ongoing medical supervision. While Austedo can effectively mitigate symptoms, it is not a cure, and its administration requires the expertise and guidance of a healthcare professional to ensure appropriate usage and patient safety.